Onasemnogene Abeparvovec
Other Drugs For Disorders Of The Musculo-Skeletal System
Sold as Itvisma · Zolgensma
- Drug class
- Other Drugs For Disorders Of The Musculo-Skeletal System
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 3
Overview
Onasemnogene Abeparvovec is an active pharmaceutical ingredient in the Other Drugs For Disorders Of The Musculo-Skeletal System group (M09AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | May 15, 2026 |
| EU European Union | EMA | 1 | August 28, 2025 |
| CA Canada | Health Canada | 1 | December 23, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
Zolgensma is indicated for the treatment of: - patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or - patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
How to take
EUEuropean Union· EMA
1 product
Uses
Zolgensma is indicated for the treatment of: - patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or - patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Onasemnogene Abeparvovec. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011223 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/004750 · revised August 28, 2025
- [3]Health Canada (DPD) · 02509695 · revised December 23, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.